ESMO 2025 movers – FDA volte-face to the rescue
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Full data from Edge-Gastric are presented at ESMO.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.